




intravacc

innovating vaccines

Vaccine Delivery Needle free vaccination



Our strength is in the core of vaccine development, allowing you to focus on your strengths.

Introduction

The Intravacc vaccine delivery program aims at optimizing the efficacy and accessibility of and access to vaccines. By combining innovation and knowledge into a product-oriented approach, Intravacc contributes to improved vaccine delivery worldwide.

A need for innovative delivery methods

Vaccination by needle and syringe has several drawbacks amongst needle stick injuries and spreading of disease through reused needles. The need for skilled personnel forms another disadvantage especially when it comes to mass vaccination. Moreover, injections may cause stress, fear and concern in children and their parents, which could affect compliance to vaccination programs. Needle free vaccine administration can prevent needle stick injuries, spreading of disease through the reuse of needles and often does not require skilled personnel to perform the injection. Therefore, the vaccine delivery program at Intravacc works towards safe, affordable, efficacious and thermostable needle free vaccines. Moreover, we strive to reduce the number of injections by combining multiple vaccines in one shot.

Vaccine delivery at Intravacc

The Intravacc vaccine delivery activities consist of:

- Subcutaneous and intramuscular vaccination using injectables and jet injectors
- Dermal/transcutaneous vaccination utilizing microneedles
- Mucosal vaccination

Subcutaneous and intramuscular vaccination using injectables and jet injectors

Most vaccines are delivered by the intramuscular route and some by the subcutaneous route. Since both routes are commonly used for vaccination, it is a logical target for novel delivery strategies. Intravacc has tested and further developed various devices and delivery systems (e.g. jet injectors, subcutaneous implants like the Bioneedles™) to further promote and accommodate needle free delivery. Some of these ensure the thermostabilization of the antigen, thereby eliminating the need for a cold chain in eventual vaccine distribution.





Bridging the gap in translational vaccinology.

Intravacc transfers its vaccine (delivery) technology (red) and expertise (blue) to major companies around the world.

Dermal and transcutaneous vaccination with microneedles

Dermal and transcutaneous vaccination takes advantage of the skin as a highly immunogenic organ. The main challenge is to transport antigens through the stratum corneum – the upper layer of the skin – to the Langerhans cells located in the epidermis. At Intravacc various approaches are being evaluated; amongst which, minimal-invasive delivery using microneedles of all sorts. The translational profile of Intravacc allows us to (co-) develop promising delivery technologies from lead phase up to early clinical development.

Mucosal vaccination; exploring the intranasal, sublingual and pulmonary delivery routes

Mucosal delivery is an attractive route because mucosa's have a large, easy accessible surface area and their own immunological competence. However, mucosa's are generally exposed to a large variety of environmental antigens and have developed tolerizing systems that prevent an overreaction of the immune system. Strong mucosal adjuvants or live attenuated vaccines are often required to induce a mucosal immune response. Progress in the production of tablets and powders provide new opportunities for intranasal, sublingual and pulmonary delivery. Moreover, the (co-) development of new delivery devices (e.g. nasal sprays) holds further promise.

Partnering in vaccine delivery

Intravacc aims to (co-)develop promising leads further along the vaccine development chain. We are specialized in taking innovative vaccine concepts to the next level. Please contact us for more information and tailor-made solutions.

Intravacc

The Institute for Translational Vaccinology is a renowned, not-for-profit R&D organization. With our unique capabilities and infrastructure, we are able to optimize vaccines, vaccine processes and vaccine technologies. Our aim is to increase equality in access to vaccines throughout the world in order to contribute to public health. We achieve this by transferring our knowledge and technologies to public and private partners worldwide and through collaborative R&D. A team of 150 professionals is at your disposal at Science Park Bilthoven in The Netherlands.

Contact

Intravacc

Antonie van Leeuwenhoeklaan 9
T: +31 (0) 30 7920 300
P.O. Box 450
3720 AL BILTHOVEN
businessdevelopment@intravacc.nl
www.intravacc.nl